TSXV:LBL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. More Details


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Lattice Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LBL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.7%

LBL

-6.4%

CA Biotechs

-1.2%

CA Market


1 Year Return

75.0%

LBL

61.1%

CA Biotechs

-5.5%

CA Market

Return vs Industry: LBL exceeded the Canadian Biotechs industry which returned 56.5% over the past year.

Return vs Market: LBL exceeded the Canadian Market which returned -3.6% over the past year.


Shareholder returns

LBLIndustryMarket
7 Day16.7%-6.4%-1.2%
30 Day-12.5%-10.0%0.4%
90 Day-22.2%11.0%-0.3%
1 Year75.0%75.0%61.1%61.1%-2.1%-5.5%
3 Year-46.2%-46.2%8.2%8.2%3.9%-6.2%
5 Yearn/a-23.9%-23.9%32.3%12.0%

Price Volatility Vs. Market

How volatile is Lattice Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lattice Biologics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Lattice Biologics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lattice Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of LBL's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Lattice Biologics regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Lattice Biologics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lattice Biologics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of LBL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Lattice Biologics competitive advantages and company strategy can generally be found in its financial reports archived here.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Lattice Biologics performed over the past 5 years?

46.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LBL is currently unprofitable.

Growing Profit Margin: LBL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LBL is unprofitable, but has reduced losses over the past 5 years at a rate of 46% per year.

Accelerating Growth: Unable to compare LBL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LBL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: LBL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Lattice Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: LBL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: LBL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: LBL has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: LBL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LBL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: LBL has less than a year of cash runway if free cash flow continues to grow at historical rates of 62.7% each year.


Next Steps

Dividend

What is Lattice Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LBL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LBL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LBL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LBL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LBL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average board tenure


CEO

Guy Cook (55 yo)

6.83yrs

Tenure

US$360,000

Compensation

Mr. Guy S. Cook has been the Chief Executive Officer of Lattice Biologics Ltd. since December 23, 2013 and also serves as its President since December 2015. Mr. Cook served as the Chief Executive Officer a ...


CEO Compensation Analysis

Compensation vs Market: Guy's total compensation ($USD360.00K) is above average for companies of similar size in the Canadian market ($USD171.35K).

Compensation vs Earnings: Guy's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Guy Cook
Chairman of the Board6.83yrsUS$360.00k35.78%
$ 1.4m
Donald McInnes
Independent Director26.75yrsno data0.096%
$ 3.7k
Kevin Loud
Independent Director3.33yrsno data2.08%
$ 79.9k
Kerry Zang
Chair of the Scientific Advisory Board 3.33yrsno datano data

3.3yrs

Average Tenure

Experienced Board: LBL's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LBL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.2%.


Top Shareholders

Company Information

Lattice Biologics Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lattice Biologics Ltd.
  • Ticker: LBL
  • Exchange: TSXV
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$3.847m
  • Shares outstanding: 128.22m
  • Website: https://www.latticebiologics.com

Location

  • Lattice Biologics Ltd.
  • 512 East Madison Avenue
  • Suite 101
  • Belgrade
  • Montana
  • 59714
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LBLTSXV (TSX Venture Exchange)YesVoting Common SharesCACADDec 2015
B5G2DB (Deutsche Boerse AG)YesVoting Common SharesDEEURDec 2015
LBLT.FOTCPK (Pink Sheets LLC)YesVoting Common SharesUSUSDDec 2015

Biography

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. Th ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 00:04
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.